Skip to content

Effects of transdiagnostic group therapy on mental health of psychiatric inpatient veterans

Effect of transdiagnostic group therapy on the mental health indices of psychiatric inpatient veterans

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200411047023N2
Enrollment
24
Registered
2026-04-28
Start date
2026-06-05
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Veterans with psychiatric disabilities: The psychiatric problems and mental health issues of hospitalized veterans in the psychiatric wards, which encompass a wide range of symptoms and disorders. Common conditions in these patients include post-traumatic stress disorder (PTSD), depression, anxiety, and other trauma-related and mood disorders..

Interventions

Intervention 1: Intervention group: Participants in this group will receive routine inpatient care in addition to a structured metacognitive/transdiagnostic group therapy program based on the Yalom an

Sponsors

Bagheiat-allah University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: More than 18 years of age Hospitalized in veteran's psychiatric ward Stable physical and psychiatric condition (no need for critical care) Written consent for participating in the study

Exclusion criteria

Exclusion criteria: Active suicidal ideation Severe active psychosis Severe agitation or aggression Cognitive impairment preventing participation in group sessions No further interest in continuing the study

Design outcomes

Primary

MeasureTime frame
Depression score in Patient Health Questionnaire-9. Timepoint: At the beginning of study entry and upon completion of the intervention for each participant (14 days after the start of the intervention or at the time of discharge). Method of measurement: Patient Health Questionnaire-9 (PHQ9).;Anxiety score in Generalized Anxiety Disorder-7 Questionnaire (GAD7). Timepoint: At the beginning of study entry and upon completion of the intervention for each participant (14 days after the start of the intervention or at the time of discharge). Method of measurement: Generalized Anxiety Disorder-7 Questionnaire (GAD7).;Quality of life score in WHO - Quality of Life - Brief Questionnaire (WHOQOL-BREF). Timepoint: At the beginning of study entry and upon completion of the intervention for each participant (14 days after the start of the intervention or at the time of discharge). Method of measurement: WHO - Quality of Life - Brief Questionnaire (WHOQOL-BREF).;Hope to life score in Snyder's Adult Hope Scale. Timepoint: At the beginning of study entry and upon completion of the intervention for each participant (14 days after the start of the intervention or at the time of discharge). Method of measurement: Snyder's Adult Hope Scale.;Length of hospital stay. Timepoint: After the discharge of the last patient from the hospital. Method of measurement: Length of hospital stay.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHossein Mohaddes Ardabili

Mashhad University of Medical Sciences

Myhhoo@gmail.com+98 51 3700 2202

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026